Skip to content
LATEST
Health

Tonabersat trial posts Phase 2 DME results to registry

The completed mid-stage study was sponsored by Jaeb Center for Health Research, NIH, NEI and the Juvenile Diabetes Research Foundation.

Tonabersat trial posts Phase 2 DME results to registry

ClinicalTrials.gov posted results on Nov. 20 for NCT05727891, a completed Phase 2 trial evaluating Tonabersat in diabetic macular edema, the federal clinical-trial registry showed.

The update matters because Phase 2 trials are mid-stage human studies that usually examine safety, dosing and early signs of efficacy before larger confirmatory research.

Diabetic macular edema, or DME, is a diabetes-related eye condition involving fluid in the macula, the central part of the retina used for detailed vision. The registry record identifies Tonabersat as the intervention under evaluation for that condition.

The study was sponsored by Jaeb Center for Health Research, the National Institutes of Health, the National Eye Institute and the Juvenile Diabetes Research Foundation, according to ClinicalTrials.gov registry data.

The posting confirms that the trial is completed and that results have been added to the public registry. It does not, by itself, establish whether Tonabersat improves vision, retinal swelling or safety outcomes in DME patients.

The next evidence step is the content of the posted results and any peer-reviewed publication or regulatory filing that reports endpoints, adverse events and the enrolled patient population.

Source: ClinicalTrials.gov clinical registry, Nov. 20, 2026

Atlas360 reports health research and does not provide medical advice.

More stories

Latest news